Childhood cancers trials in Japan

In Japan 48 Also abroad 2459

48 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Chuo Ku, Kashiwa
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Chuo-ku, Kyoto, Nankoku, Sapporo, Tokyo, Yokohama
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama, Morioka, Nagoya, Osaka, Sapporo, Shinjuku-ku, Suita-shi, Sunto-gun, Toon-Shi
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Fukuoka, Saitama, Yokohama
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Bunkyo, Minato
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Kobe
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Where
Chiba, Chuo-ku, Fukuoka-shi, Fukuoka, Kanagawa, Kashiwa-shi, Matsuyama, Numakunai, Saitama, Sakaishi
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00
No phaseTaking people
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
Where
Bunkyo Ku, Kurume, Osaka, Suita
Age
15 years to 15 years
People
30
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07378969
Phase 1/2Taking people
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Where
Fukuoka, Fukushima, Kanazawa, Kashiwa, Kobe, Maebashi, Nagoya, Sapporo, Tokyo, Yamagata, Yoshida
Age
2 years and over
People
420 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Bunkyō City, Chiba, Chuo Ku, Fukuoka, Isehara City, Kanagawa, Kyoto, Minato-ku, Nagoya, Okayama, Osaka, Sapporo, Shibuya-ku, Shimotsuke, Shinjuku, Tennoji-Ku, Yamagata
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Bunkyō City, Kashiwa, Okayama
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto, Mie, Nagoya, Osaka, Saitama, Shizuoka, Tōhoku, Tokyo
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 1/2Taking people
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Where
Bunkyō City, Chūōku, Kashiwa
Age
12 years and over
People
83 worldwide
Run by
AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00
Phase 2Taking people
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Where
Akashi, Bunkyo-ku, Chiba, Chuo-ku, Fukuoka, Hidaka, Hiroshima, Kashiwa, Kitaadachi-gun, Koto-ku, Koto-Ku, Kurume, Kyoto, Matsuyama, Okayama, Osaka, Sapporo, Shinjuku-ku, Suita, Takatsuki, Yokohama, Yufu
Age
16 years and over
People
70 worldwide
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT04566380
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka, Sapporo, Toyohashi, Yamagata
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
Bunkyō City, Kōtoku
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1/2Taking people
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Where
Chiba, Chuo Ku, Fukuoka, Hiroshima, Kanazawa, Kashiwa, Kyoto, Okayama, Osaka, Sakai, Sapporo, Sendai, Sunto-gun, Tsu, Yokohama
Age
12 years and over
People
50
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07734116
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Where
Fukuoka, Hokkaido, Tokyo
People
64 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602777
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 2Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Where
Fukuoka, Kyoto, Okayama, Sapporo Hokkaido, Sendai, Tokyo
People
1,500 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT05041309 · EU 2023-507041-28-00
No phaseTaking people
Acute Ischemic Stroke in Patients With Active Cancer
Where
Suita
People
500
Run by
Osaka University
See details and how to joinNCT07819526
Phase 3Taking people
Study of Out of Specification for Tisagenlecleucel
Where
Aomori, Bunkyo Ku, Chiba, Chuo Ku, Fuchū, Fukuoka, Gifu, Hamamatsu, Hiroshima, Ishikawa, Izumi, Izumisano, Izumo, Kita-gun, Kobe, Kumamoto, Kurashiki, Kyoto, Matsumoto, Minato Ku, Nagasaki, Nagoya, Niigata, Nishinomiya, Okayama, Osaka, Saitama, Sakai, Sapporo, Sendai, Setagaya-ku, Shinjuku Ku, Suita, Tōon, Tsu, Tsukuba, Wakayama, Yokohama, Yufu
Age
0 years to 100 years
People
200 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04094311
Phase 3Taking people
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Where
Chiba-sgi, Chuo-ku, Higashiku, Hiroshima, Kobe, Kyoto, Niigata, Nishinomiya, Hyogo, Osaka, Saitama, Sapporo, Sendai, Shinjuku-ku, Tokyo, Tsukuba, Yokohama
People
1,780 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT03067181
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Where
Chuo-Ku, Fukuoka, Kashiwa-shi, Kyoto, Nagoya, Okayama, Sapporo, Sendai
Age
12 years and over
People
100 worldwide
Run by
AbbVie
See details and how to joinNCT07196644 · EU 2024-518871-74-00